Drug Search Results
Using advanced filters...
Advanced Search [+]

CACIPLIQ-20

Alternative Names: cacipliq-20, cacipliq20, cacipliq 20
Latest Update: 2024-02-13
Latest Update Note: Clinical Trial Update

Product Description

CACIPLIQ20 is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates.

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Organ, Tissue, Regeneration, Repair and Replacement
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CACIPLIQ-20

Countries in Clinic: France

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Acute Pain|Chronic Pain|Edema|Facial Pain|Keloid|Skin Ulcer|Wounds, Stab

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MATRISCAR

P3

Recruiting

Acute Pain|Edema|Facial Pain|Chronic Pain|Wounds, Stab|Skin Ulcer|Keloid

2024-10-01

Recent News Events